Article thumbnail
Location of Repository

Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors

By Randall E Harris, Joanne Beebe-Donk and Galal A Alshafie
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2529335
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). Anti-inflammatory drugs in the 21st century. Subcell Biochem
  2. (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res
  3. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (Review). Oncol Rep
  4. (2005). Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
  5. (1982). Case Control Studies.
  6. Chinthalapally RV: Role of synthetic and naturally occurring cyclooxygenase inhibitors in colon cancer prevention.
  7. (2004). Clinical Trials: Nail-biting time for trials of drugs. Science
  8. (2007). Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Subcell Biochem
  9. (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
  10. (2005). Does the dose make the poison? Science
  11. (1995). Hla T: Expression of cylcooxygenase-1 and -2 in colorectal cancer. Cancer Res
  12. (1992). Human cyclooxygenase-2 cDNA.
  13. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature
  14. (2006). Investigators: Celecoxib for the prevention of sporadic colorectal adenomas.
  15. (2005). JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
  16. (2002). Lefkowith JB: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
  17. (2005). Logistic Regression Procedure. Statistical Analysis System (SAS);
  18. (2005). Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol
  19. (2005). Pickle LW: Annual report to the nation on the status of cancer, 1975-featuring population-based trends in cancer treatment.
  20. (2006). PreSAP Trial Investigators: Celecoxib for the prevention of colorectal adenomatous polyps.
  21. (1994). Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer and Metas Rev
  22. (1994). RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenoma and adenocarcinoma. Gastroenterology
  23. (2003). RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor, celecoxib.
  24. (2007). Strategies for colon cancer prevention: combination of chemopreventive agents. Subcell Biochem
  25. (2003). The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology
  26. (2001). Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors.
  27. (2007). Verburg KM: Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
  28. (2004). Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.